PT - JOURNAL ARTICLE AU - Barros-Martins, Joana AU - Hammerschmidt, Swantje I. AU - Cossmann, Anne AU - Odak, Ivan AU - Stankov, Metodi V. AU - Ramos, Gema Morillas AU - Dopfer-Jablonka, Alexandra AU - Heidemann, Annika AU - Ritter, Christiane AU - Friedrichsen, Michaela AU - Schultze-Florey, Christian AU - Ravens, Inga AU - Willenzon, Stefanie AU - Bubke, Anja AU - Ristenpart, Jasmin AU - Janssen, Anika AU - Ssebyatika, George AU - Bernhardt, Günter AU - Münch, Jan AU - Hoffmann, Markus AU - Pöhlmann, Stefan AU - Krey, Thomas AU - Bošnjak, Berislav AU - Förster, Reinhold AU - Behrens, Georg M. N. TI - Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination AID - 10.1101/2021.06.01.21258172 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.01.21258172 4099 - http://medrxiv.org/content/early/2021/06/03/2021.06.01.21258172.short 4100 - http://medrxiv.org/content/early/2021/06/03/2021.06.01.21258172.full AB - Cerebral venous thrombosis was reported as a rare but serious adverse event in young and middle-aged vaccinees following immunization with AstraZeneca’s ChAdOx1-nCov-19 vaccine. As a consequence, several European governments recommended using this vaccine only in individuals older than 60 years leaving millions of ChAd primed individuals with the decision to either receive a second shot of ChAd or a heterologous boost with mRNA-based vaccines. However, such combinations have not been tested so far. We used Hannover Medical School’s COVID-19 Contact (CoCo) Study cohort of health care professionals (HCP) to monitor ChAd primed immune responses before and three weeks after booster with ChAd or BioNTech/Pfizer’s BNT162b2. Whilst both vaccines boosted prime-induced immunity, BNT induced significantly higher frequencies of Spike-specific CD4 and CD8 T cells and, in particular, high titers of neutralizing antibodies against the B.1.1.7, B.1.351 and the P.1 variants of concern of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the German Center for Infection Research TTU 01.938 (grant no 80018019238 to G.M.N.B and R.F) by Deutsche Forschungsgemeinschaft, (DFG, German Research Foundation) Excellence Strategy EXC 2155 RESIST to RF (Project ID39087428), by funds of the State of Lower Saxony (14-76103-184 CORONA-11/20) to RF, by funds of the BMBF (NaFoUniMedCovid19 FKZ: 01KX2021; Projects B-FAST) to RF and Deutsche Forschungsgemeinschaft, Project 158989968 - SFB 900/3 (Projects B1 to RF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Internal Review Board of Hannover Medical School (institutional review board no. 8973_BO-K_2020, amendment Dec 2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.